Clinical Trial

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

- Based on a per-protocol interim analysis of safety and efficacy data, the Independent Data Monitoring Committee (IDMC) recommended that…

5 months ago

Grit Biotechnology Receives U.S. FDA Clearance of Investigational New Drug Application for GT201, a genetically engineered TIL, following its Chinese IND Approval

SHANGHAI, Aug. 30, 2024 /PRNewswire/ -- Grit Biotechnology, a leading clinical-stage cell therapy company focusing on tumor-infiltrating lymphocyte (TIL) therapies, has…

5 months ago

Quantum Biopharma Announces Celly Nutrition Launches unbuzzd(TM) Grab-and-Go Stick Packs on Amazon.com so you can “own NOW and what’s NEXT”

TORONTO, ON / ACCESSWIRE / August 30, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical…

5 months ago

Celly Nutrition Launches unbuzzd Grab-and-Go Stick Packs on Amazon.com so You Can “Own Now and What’s Next”

Vancouver, British Columbia--(Newsfile Corp. - August 29, 2024) - Celly Nutrition Corp. ("Celly Nutrition" or the "Company") proudly announces the…

5 months ago

Zomedica’s Assisi Loop(R) Product Line Designated as Fear Free(TM) Preferred Product

Assisi’s tPEMF™ technology aligns with Fear Free’s mission to “prevent and alleviate fear, anxiety, and stress in pets” ANN ARBOR, MI…

5 months ago

The International Myeloma Foundation (IMF) Brings Back ‘Do You #kNOwMyeloma?’ for Blood Cancer Awareness Month 2024

LOS ANGELES, Aug. 29, 2024 (GLOBE NEWSWIRE) -- With Blood Cancer Awareness Month coming up this September, the International Myeloma…

5 months ago

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

ATLANTA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs…

5 months ago

Safety Shot Clinical Data Results Confirm Breakthrough in Dramatic Reduction of Morning-After Symptoms Associated with Excessive Drinking

The Company Showed a Substantial Reduction in the Physical, Negative Characteristics that Accompany Heavy Drinking in its Recent Groundbreaking, Clinical…

5 months ago

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

RAMAT GAN, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company…

5 months ago

ORYZON to Provide Corporate Progress Updates at Several Events in September

German Fall Conference 2024European College of Neuropsychopharmacology (ECNP) congress 2024Sachs Annual Biotech in Europe Forum 2024 MADRID, Spain and CAMBRIDGE,…

5 months ago